Searchable abstracts of presentations at key conferences in endocrinology

ea0103p122 | Miscellaneous/Other 2 | BSPED2024

Safety of lanreotide in infants with congenital hyperinsulinism

Malhotra Neha , Yan Georgina , Morgan Kate , Gilbert Clare , Gan Chin , Dastamani Antonia

Background: Lanreotide, a prolonged-release somatostatin analogue, has been used off-label for nearly a decade to treat congenital hyperinsulinism (CHI) cases resistant to diazoxide. Lanreotide’s side-effects include diarrhea, topical allergic reactions, hepatitis, gallstones, growth suppression, hypothyroidism, and gastrointestinal dysmotility. However, there are limited case reports documenting its safety in infants with CHI.Objective: To evaluate...